Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt ...

She has resigned from the former; the latter does not matter since 23andMe’s equity could be wiped out. If persistence pays off, a company that started out as little more than an intriguing idea and a ...

Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical company at $6.7 billion, writes ...

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc. Under the terms of the proposed transaction, ...

will combine their branded drugs businesses that include Endo's testosterone injection Aveed as well as Mallinckrodt's Acthar Gel and kidney disease therapy Terlivaz. Advt The merger will "create ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal ... Read more about Endo locking into a merger agreement in the Philadelphia Business Journal.

Wachtell Lipton Rosen & Katz and Davis Polk & Wardwell have scored lead roles on the $6.7bn merger of drugmakers Mallinckrodt and Endo. Wachtell is serving as lead counsel for Dublin-based ...

In addition, Endo has entered into an agreement to sell the international pharmaceutical business to Knight Therapeutics Inc. for $99 million. The deal will reduce costs and expand access to new ...

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc. Under the terms of the proposed transaction ...